Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneNathalie A. Johnson, Randy D. Gascoyne, Graham W. Slack et al.|Journal of Clinical Oncology|2012Cited by 971
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramShimin Hu, Ken H. Young, J. Han van Krieken et al.|Blood|2013Cited by 677
Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphomaSarah E. Arthur, Ryan D. Morin, Aixiang Jiang et al.|Nature Communications|2018Cited by 148
Molecular Determinants of Clinical Outcomes In a Real-World Diffuse Large B-cell Lymphoma PopulationWaleed Alduaij, David W. Scott, Brett Collinge et al.|Blood|2022Cited by 89
Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patternsKostiantyn Dreval, Ryan D. Morin, Laura K. Hilton et al.|Blood|2023Cited by 53